The US Market and LBP Development

US companies have long been at the forefront of Microbiome drug development, thanks to robust support from academic research and substantial funding from the National Institutes of Health (NIH). Coupled with this, is the prominence of Live Biotherapeutic Products (LBP), which have consistently been the leading therapeutic class for Microbiome drug developers.

LBP Development in the US Market Report

This report covers:

  • A detailed US geographic overview, including breakdowns by company type and headquarters location
  • Analysis of US funding trends since 2023, categorized by type, deal value, and therapeutic class
  • Comparative analysis of LBPs in clinical trials since 2014, alongside WEDPs
  • Comprehensive overview of therapeutic classes for LBPs

You May Also Be Interested In…

Learn More About Microbiome

What is Beacon Microbiome?
  • The Most Comprehensive Way to Search the Microbiome Drug Development Landscape: Unique search ontologies based on Microbiome drug and trial characteristics
  • Market Leading Approach to Microbiome Preclinical & Clinical Data Curation: Manual curation of key Microbiome research and development data points by Microbiome research scientists
  • Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Microbiome company and deal data based on their pipeline and technologies.
  • Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
Learn More About Beacon Microbiome

What is Beacon?

Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.

Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements

Find out more

Menu
Search Icon
Close Icon
Search